BPC-157

BPC-157 is a partial sequence of a protein found in human gastric juice, and it is unusually stable in acid, which is why oral dosing is plausible at all. The best-characterised mechanism is activation of the VEGFR2-Akt-eNOS axis, producing new capillary growth into damaged tissue; rodent work also shows increased FAK-paxillin signalling and fibroblast outgrowth in tendon explants, upregulation of the EGR-1/NAB2 early growth response pathway, and increased growth hormone receptor expression on tendon fibroblasts. Separate lines of animal work describe modulation of dopaminergic, serotonergic and GABAergic systems and protection of the gut-brain axis, which is where the mood and gut claims come from. All of this is established in rodents and in vitro. None of it has been confirmed in a controlled human trial, and the human pharmacokinetics are essentially unknown.

Targets: VEGFR2, Nitric oxide / eNOS pathway, FAK-paxillin signalling, EGR-1 / NAB2, Growth hormone receptor (tendon fibroblasts)

• · Almost every anecdotal protocol lands at 250-500 mcg per dose, so 250-1000 mcg per day total. Higher does not obviously do more, and the rodent dose-response is famously flat across several orders of magnitude.
• · This is the most popular approach for a specific tendon or ligament. Injecting into a tendon or joint space is a sterility and structural risk, not a benefit.
• · Used for reflux, IBD-type symptoms and NSAID-related gut damage. The stability of the peptide in gastric juice is the rationale, and reconstituted solution is usually just swallowed.

Work out your exact syringe units →

• commonInjection-site stinging or redness— Usually settles within an hour and improves with slower injection.
• uncommonTransient fatigue or heaviness in the first few days— Commonly reported at higher daily totals.
• uncommonHeadache— Plausibly related to the nitric oxide and vasodilatory activity.
• uncommonLoose stools with oral dosing— Often improves if the dose is taken with a small amount of water rather than on a completely empty stomach.

• Active or recently treated malignancy - a compound whose headline mechanism is angiogenesis is a poor choice around tumour tissue, and there is no human safety data here.
• Unexplained pain that has not been imaged - masking a stress fracture or a full-thickness tear with a repair peptide is how people turn a six-week problem into a surgical one.

• synergytb-500 — The default soft-tissue stack; BPC-157 drives local angiogenesis while TB-500 acts more systemically on cell migration.
• synergykpv — Frequently paired orally for inflammatory bowel symptoms.
• synergyghk-cu — Combined for wound and skin repair where matrix remodelling matters as much as blood supply.

• · No routine bloodwork is established for BPC-157.
• · Track the injury objectively - range of motion, load tolerated, pain at a fixed test movement - rather than relying on how the week felt.

Not an approved drug in the US or EU and sold overwhelmingly as a research chemical. In April 2026 the FDA removed BPC-157 from the Category 2 compounding list, and on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding it to the 503A Bulks List. That vote is non-binding and the FDA has not yet acted on it. WADA-prohibited for tested athletes.

• Sikiric et al., stable gastric pentadecapeptide BPC 157 and the gut-brain axis (review series, Current Pharmaceutical Design / Current Medicinal Chemistry) (review)
• Chang et al. 2011, BPC 157 promotes tendon fibroblast outgrowth, survival and migration, Journal of Applied Physiology (preclinical)
• FDA Pharmacy Compounding Advisory Committee, 23-24 July 2026 meeting materials on BPC-157 free base and acetate (guideline)

The Core entry says VEGFR2 and nitric oxide. The detail worth having is that BPC-157 does not behave like a classical receptor ligand at all. No binding constant has ever been published for it at VEGFR2 or at anything else. What the rodent work actually shows is that exposure increases VEGFR2 expression and phosphorylation, which then drives the Akt-eNOS arm and produces nitric oxide locally. That distinction predicts the clinical picture people describe. A permissive amplifier of an already-running repair process does very little in uninjured tissue, and its dose-response is flat, because you are not saturating a receptor. BPC-157's rodent dose-response is famously flat across three or four orders of magnitude - nanograms and micrograms per kilogram producing the same effect - which is not how a saturable agonist behaves and is a large part of why the pharmacology community is sceptical. The second arm is cytoskeletal. In tendon explants BPC-157 increases FAK phosphorylation and paxillin turnover, which is the exact machinery a fibroblast uses to form and release focal adhesions as it crawls. That is why the tendon effect appears as faster fibroblast outgrowth, survival and migration rather than as more collagen per cell. The same work shows upregulation of growth hormone receptor on tendon fibroblasts, which is the honest basis for stacking it with a GH secretagogue - the peptide makes the tissue more responsive to GH rather than raising GH itself. The third arm is the nitric oxide system as a whole, and it is the most distinctive thing in the pharmacology. BPC-157 counteracts L-NAME-induced hypertension and L-arginine-induced hypotension in the same animals. That bidirectionality means it acts as an NO-system stabiliser rather than a donor, which is also why the headache some people get is not simply a vasodilator headache. The caveat that must travel with every sentence above: the overwhelming majority of it comes from one group in Zagreb using their own models, and it has never been independently replicated at scale or confirmed in a controlled human trial.

The most common failure is not a side effect, it is a diagnosis. People run BPC-157 into pain that has never been imaged, feel less pain because the peptide is genuinely anti-inflammatory, keep loading the tissue, and convert a partial tear or a stress reaction into something surgical. Image first. The second failure is product identity. This is an unregulated market and BPC-157 is the most counterfeited peptide in it. If you get nothing at all from a 500 mcg twice-daily protocol over six weeks, the most likely explanation is the vial, not the dose. Escalating to 2 mg daily against a flat rodent dose-response curve is not a rational response - buying from a vendor with third-party mass spec is. The third failure is expectation calibration. Gut symptoms often move in three to seven days and that fast response gets generalised. Tendon and ligament remodelling is a six-week question at minimum, and the people who quit at two weeks concluding it does nothing are quitting before the endpoint they cared about could have moved. The genuine safety concern, and it is theoretical rather than documented, is the angiogenesis. A compound whose headline mechanism is new blood vessel growth is a poor thing to run with an undiagnosed mass or a recent cancer history. There is no human safety data to reassure you either way.

• VEGFR2 (KDR) — No binding constant published. BPC-157 upregulates receptor expression and phosphorylation; direct ligand binding has never been demonstrated.

  Drives the Akt-eNOS-nitric oxide axis in endothelial cells, producing capillary ingrowth into damaged tissue. This is the single best-characterised downstream effect.

• eNOS / nitric oxide system — Not a receptor interaction; modulatory and bidirectional

  Opposes both NOS blockade and excess NO substrate load, which is why it reads as a stabiliser of vascular tone rather than a vasodilator.

• FAK-paxillin focal adhesion complex — Not characterised

  Increases fibroblast adhesion turnover and migration - the mechanism behind tendon explant outgrowth.

• EGR-1 / NAB2 early growth response pathway — Not characterised

  Upregulates the immediate-early transcriptional programme that switches on growth factor and cytokine production after injury.

• Growth hormone receptor on tendon fibroblasts — Not characterised

  Increased receptor expression, making the tissue more responsive to circulating GH rather than raising GH itself.

• Dopaminergic, serotonergic and GABAergic systems — Not characterised; effects shown in rodent brain regional synthesis studies

  The mechanistic basis for the mood and gut-brain claims. Whether this reflects central penetration or vagal signalling from the gut has never been resolved.

• PL-14736 (BPC-157) phase 2 programme in ulcerative colitis, Pliva Phase 2

  Mucosal healing and disease activity in ulcerative colitis. The programme was discontinued and no full trial report has ever appeared in the indexed literature, which is why it can be described but not cited.

• Uncontrolled human pilot studies of BPC-157 (pooled) Pilot / uncontrolled · 2026

  A 2026 formulation review reports that all available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none using a standardised pharmaceutical preparation. There is no completed phase 2 efficacy trial for any indication.

Days one to three: nothing measurable for connective tissue. Injection-site stinging is the main thing you notice. Some people report a mild heaviness or fatigue in the first few days at the higher end of dosing. Days three to seven: this is where gut symptoms move if they are going to - reflux, NSAID-related irritation, IBD-type discomfort. It is the fastest signal the compound produces and the one most likely to be real rather than placebo, because it is a mucosal effect on a fast-turnover tissue. Weeks two to three: the first honest window for a tendon or joint. Judge it by load tolerated at a fixed test movement, not by how the week felt. Weeks four to six: the decision point. If a repeatable loading test has not improved by week six on a verified product, stop. Running longer against a flat dose-response is not a plan. After stopping: tissue effects are reported to persist, which is consistent with a drug that remodels tissue rather than masking symptoms - but this is anecdote, and no washout study exists.

The BPC-157 plus TB-500 pairing is the default because the mechanisms genuinely do not overlap: BPC-157 raises local blood supply, TB-500 frees actin so cells can move into the space that creates. Running both is defensible on mechanism even though neither has human efficacy data. With KPV orally for gut work the logic is cleaner still - BPC-157 for mucosal repair, KPV to shut down the NF-kB signal driving the damage. That is the one stack in this class where both compounds have a specific, non-redundant job. With GHK-Cu the target is matrix quality rather than speed, which matters for scars and post-surgical wounds. Do not stack GHK-Cu injectable long-term alongside anything, though - the copper load is the constraint, not the peptide. With a GH secretagogue such as CJC-1295 or ipamorelin there is a real mechanistic argument, because BPC-157 upregulates growth hormone receptor on tendon fibroblasts. That makes the tissue more responsive to whatever GH you already have. It is still theory. The one stack that deserves scepticism is BPC-157 with any of its own rebrands. BPC-157, BPC-157 arginate and pentadeca arginate are the same peptide. Running two of them is splitting one dose across two invoices.

Against TB-500: BPC-157 is local, daily and cheap; TB-500 is systemic, weekly and more expensive, and carries a more serious theoretical cancer concern because thymosin beta-4 overexpression tracks with metastatic potential. For a single identified tendon, BPC-157 is the more targeted choice. Against its own rebrands: identical peptide, different counter-ion or different marketing name. Buy on price and certificate of analysis, not on the label. Against ARA-290 for nerve pain: not close. ARA-290 has randomised placebo-controlled human trials with objective nerve-fibre imaging endpoints. BPC-157 has rodent sciatic nerve models. If the problem is small fibre neuropathy, the evidence points at the other compound. Against collagen peptides plus loaded rehab for tendinopathy: the boring option has better human evidence. Fifteen grams of gelatin with vitamin C an hour before targeted loading has a mechanistic human study behind it; BPC-157 does not. Doing both is reasonable. Doing only BPC-157 and skipping the loading is the common and expensive mistake. Against an actual corticosteroid injection: BPC-157 will not do what a steroid does for acute inflammatory pain, and a steroid will not do what BPC-157 is claimed to do for tissue quality. They are answers to different questions, and steroids are known to weaken tendon over repeated exposure.

$25–$90/month. Order-of-magnitude estimate from typical grey-market vial pricing at 250-500 mcg twice daily, not price-checked in the preparation of this entry. Compounding pharmacy pricing where available runs several times higher.

• ?No human tmax, volume of distribution, clearance figure, protein binding or oral bioavailability exists by any route. Everything in the pharmacokinetics block above is from rats and beagle dogs plus a two-subject pilot.
• ?Whether BPC-157 crosses the blood-brain barrier is unresolved. Rodent CNS effects on serotonin and dopamine synthesis are documented, but they could equally reflect gut-vagal signalling rather than central penetration.
• ?The flat rodent dose-response across several orders of magnitude has never been explained. It is either a genuinely unusual pharmacology or an artefact, and nobody has resolved which.
• ?The molecular weight of 1419.5 Da in the Core record is the free peptide mass. Vendors label by peptide base, but there is no independent verification that any given vial contains what the label says.
• ?The PL-14736 ulcerative colitis programme is widely described but no full phase 2 report is indexed, so its participant numbers and results could not be verified.
• ?Cost figures are grey-market estimates and were not price-verified in this session.
• ?No washout or persistence-of-effect study exists, so claims that benefits hold after stopping are entirely anecdotal.

• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Chang CH et al., Journal of Applied Physiology, 2011 · PMID 21030672

  The single most-cited tendon paper. Source of the FAK-paxillin and growth hormone receptor findings and the fibroblast outgrowth result.

• Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs He L et al., Frontiers in Pharmacology, 2022 · PMID 36588717

  The only real ADME study. Source of the sub-30-minute half-life, the 14-19 percent rat and 45-51 percent dog intramuscular bioavailability, and the urine and bile excretion routes.

• BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Mateescu DM et al., Pharmaceutics, 2026 · PMID 42198317

  The most honest recent accounting of what human data exists - fewer than 30 subjects across three uncontrolled pilots - and of the formulation problems standing between BPC-157 and a real trial.

• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing McGuire FP et al., Current Reviews in Musculoskeletal Medicine, 2025 · PMID 40789979

  A sports-medicine-facing review that sets the rodent claims against the absence of human evidence. The best single starting point for someone deciding whether to run it for a tendon.

• Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response Sikiric P et al., Gut and Liver, 2020 · PMID 31158953

  Representative of the Zagreb review series that constitutes most of the literature. Read it knowing it is the originating group summarising its own work.

• Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 Sikiric P et al., Current Medicinal Chemistry, 2012 · PMID 22300085

  The reference point for the PL-14736 ulcerative colitis story, which is the closest BPC-157 has ever come to a clinical programme.